FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Christopher Gibbons

Chief Science Officer CND Life Sciences

Wednesday 4th February 2026

Longitudinal Quantitative Studies of Phosphorylated Alpha-Synuclein

4:00 pm

Use of Syn-One Biomarker Technology to support study subject homogeneity, identify target engagement, and measure P-SYN deposition changes over time
Detection, visualization, and quantification of cutaneous misfolded alpha-synuclein
Highlight preliminary data and topline results in current trials